[1]
|
Chalder, T., Neeleman, J., Reme, S.E., Power, M. and Wessely, S. (2010) Factors Associated with Acute Fatigue in Primary Care. Psychological Medicine, 40, 1289-1295. http://dx.doi.org/10.1017/S0033291709992327
|
[2]
|
Chaudhuri, A. and Behan, P.O. (2004) Fatigue in Neurological Disorders. Lancet, 363, 978-988. http://dx.doi.org/10.1016/S0140-6736(04)15794-2
|
[3]
|
Shen, J., Barbera, J. and Shapiro, C.M. (2006) Distinguishing Sleepiness and Fatigue: Focus on Definition and Measurement. Sleep Medicine Reviews, 10, 63-76. http://dx.doi.org/10.1016/j.smrv.2005.05.004
|
[4]
|
Pantry, S.N., Medveczky, M.M., Arbuckle, J.H., Luka, J., Montoya, J.G., Hu, J., Renne, R., Peterson, D., Pritchett, J.C., Ablashi, D.V. and Medveczky, P.G. (2013) Persistent Human Herpesvirus-6 Infection in Patients with an Inherited Form of the Virus. Journal of Medical Virology, 85, 1940-1946. http://dx.doi.org/10.1002/jmv.23685
|
[5]
|
Karaivazoglou, K., Iconomou, G., Triantos, C., Hyphantis, T., Thomopoulos, K., Lagadinou, M., Gogos, C., Labropoulou-Karatza, C. and Assimakopoulos, K. (2010) Fatigue and Depressive Symptoms Associated with Chronic Viral Hepatitis Patients. Health-Related Quality of Life (HRQOL). Annals of Hepatology, 9, 419-427.
|
[6]
|
Barroso, J., Hammill, B.G., Leserman, J., Salahuddin, N., Harmon, J.L. and Pence, B.W. (2010) Physiological and Psychosocial Factors that Predict HIV-Related Fatigue. AIDS and Behavior, 14, 1415-1427. http://dx.doi.org/10.1007/s10461-010-9691-2
|
[7]
|
Kondo, K. (2006) Post-Infectious Fatigue. Japan Medical Association Journal, 49, 27-33.
|
[8]
|
U.S. Food and Drug Administration (FDA) (2001) Long term Follow-Up Of Gene Transfer Patients. 31st Biological Response Modifiers Advisory Committee Meeting Gaithersburg, Maryland. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3794b1_01.htm
|
[9]
|
Polansky, H. (2003) Microcompetition with Foreign DNA and the Origin of Chronic Disease. Center for the Biology of Chronic Disease (CBCD) Publishing.
|
[10]
|
Liu, B.H., Wang, X., Ma, Y.X. and Wang, S. (2004) CMV Enhancer/Human PDGF-Beta Promoter for Neuron-Specific Transgene Expression. Gene Therapy, 11, 52-60. http://dx.doi.org/10.1038/sj.gt.3302126
|
[11]
|
Slobedman, B. and Mocarski, E.S. (1999) Quantitative Analysis of Latent Human Cytomegalovirus. Journal of Virology, 73, 4806-4812.
|
[12]
|
Adam, G.I., Miller, S.J., Ulleras, E. and Franklin, G.C. (1996) Cell-Type-Specific Modulation of PDGF-B Regulatory Elements via Viral Enhancer Competition: A Caveat for the Use of Reference Plasmids in Transient Transfection Assays. Gene, 178, 25-29. http://dx.doi.org/10.1016/0378-1119(96)00318-6
|
[13]
|
Scarpulla, R.C. (1997) Nuclear Control of Respiratory Chain Expression in Mammalian Cells. Journal of Bioenergetics and Biomembranes, 29, 109-119. http://dx.doi.org/10.1023/A:1022681828846
|
[14]
|
Scarpulla, R.C. (1999) Nuclear Transcription Factors in Cytochrome c and Cytochrome Oxidase Expression. In: Papa, S., Guerrieri, F. and Tager, J.M., Eds., Frontiers of Cellular Bioenergetics: Molecular Biology, Biochemistry, Physiopathology, Plenum, New York, 553-591. http://dx.doi.org/10.1007/978-1-4615-4843-0_22
|
[15]
|
Ongwijitwat, S. and Wong-Riley, M.T. (2005) Is nuclear Respiratory Factor 2 a Master Transcriptional Coordinator for All Ten Nuclear-Encoded Cytochrome c Oxidase Subunits in Neurons? Gene, 360, 65-77. http://dx.doi.org/10.1016/j.gene.2005.06.015
|
[16]
|
Ongwijitwat, S., Liang, H.L., Graboyes, E.M. and Wong-Riley, M.T. (2006) Nuclear Respiratory Factor 2 Senses Changing Cellular Energy Demands and Its Silencing Down-Regulates Cytochrome Oxidase and Other Target Gene mRNAs. Gene, 374, 39-49. http://dx.doi.org/10.1016/j.gene.2006.01.009
|
[17]
|
Larsson, N.G., Wang, J.M., Wilhelmsson, H., Oldfors, A., Rustin, P., Lewandoski, M., Barsh, G.S. and Clayton, D.A. (1998) Mitochondrial Transcription Factor A Is Necessary for mtDNA Maintenance and Embryogenesis in Mice. Nature Genetics, 18, 231-236. http://dx.doi.org/10.1038/ng0398-231
|
[18]
|
Rantanen, A., Jansson, M., Oldfors, A. and Larsson, N.G. (2001) Downregulation of Tfam and mtDNA Copy Number during Mammalian Spermatogenesis. Mammalian Genome, 12, 787-792. http://dx.doi.org/10.1007/s00335-001-2052-8
|
[19]
|
McCulloch, V., Seidel-Rogol, B.L. and Shadel, G.S. (2002) A Human Mitochondrial Transcription Factor Is Related to RNA Adenine Methyltransferases and Binds S-Adenosylmethionine. Molecular and Cellular Biology, 22, 1116-1125. http://dx.doi.org/10.1128/MCB.22.4.1116-1125.2002
|
[20]
|
Falkenberg, M., Gaspari, M., Rantanen, A., Trifunovic, A., Larsson, N.G. and Gustafsson, C.M. (2002) Mitochondrial Transcription Factors B1 and B2 Activate Transcription of Human mtDNA. Nature Genetics, 31, 289-294. http://dx.doi.org/10.1038/ng909
|
[21]
|
Au, H.C. and Scheffler, I.E. (1998) Promoter Analysis of the Human Succinate Dehydrogenase Iron-Protein Gene. Both Nuclear Respiratory Factors NRF-1 and NRF-2 Are Required. European Journal of Biochemistry, 251, 164-174. http://dx.doi.org/10.1046/j.1432-1327.1998.2510164.x
|
[22]
|
Elbehti-Green, A., Au, H.C., Mascarello, J.T., Ream-Robinson, D. and Scheffler, I.E. (1998) Characterization of the Human SDHC Gene Encoding One of the Integral Membrane Proteins of Succinate-Quinone Oxidoreductase in Mitochondria. Gene, 213, 133-140. http://dx.doi.org/10.1016/S0378-1119(98)00186-3
|
[23]
|
Hirawake, H., Taniwaki, M., Tamura, A., Amino, H., Tomitsuka, E. and Kita, K. (1999) Characterization of the Human SDHD Gene Encoding the Small Subunit of Cytochrome b (cybS) in Mitochondrial Succinate-Ubiquinone Oxidoreductase. Biochimica et Biophysica Acta (BBA)—Bioenergetics, 1412, 295-300. http://dx.doi.org/10.1016/S0005-2728(99)00071-7
|
[24]
|
Khurana, T.S., Rosmarin, A.G., Shang, J., Krag, T.O., Das, S. and Gammeltoft, S. (1999) Activation of Utrophin Promoter by Heregulin via the ets-Related Transcription Factor Complex GA-Binding Protein Alpha/Beta. Molecular and Cellular Biology, 10, 2075-2086. http://dx.doi.org/10.1091/mbc.10.6.2075
|
[25]
|
Chan, R.Y., Boudreau-Larivière, C., Angus, L.M., Mankal, F.A. and Jasmin, B.J. (1999) An Intronic Enhancer Containing an N-Box Motif Is Required for Synapse- and Tissue-Specific Expression of the Acetylcholinesterase Gene in Skeletal Muscle Fibers. Proceedings of the National Academy of Sciences, 96, 4627-4632. http://dx.doi.org/10.1073/pnas.96.8.4627
|
[26]
|
O’Leary, D.A., Noakes, P.G., Lavidis, N.A., Kola, I., Hertzog, P.J. and Ristevski, S. (2007) Targeting of the ETS Factor Gabp Alpha Disrupts Neuromuscular Junction Synaptic Function. Molecular and Cellular Biology, 27, 3470-3480. http://dx.doi.org/10.1128/MCB.00659-06
|
[27]
|
Tinsley, J.M., Fairclough, R.J., Storer, R., Wilkes, F.J., Potter, A.C., Squire, S.E., Powell, D.S., Cozzoli, A., Capogrosso, R.F., Lambert, A., Wilson, F.X., Wren, S.P., De Luca, A. and Davies, K.E. (2011) Daily Treatment with SMTC1100, a Novel Small Molecule Utrophin Upregulator, Dramatically Reduces the Dystrophic Symptoms in the mdx Mouse. PLoS One, 6, e19189 http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0019189 http://dx.doi.org/10.1371/journal.pone.0019189
|
[28]
|
Faber, C.G., Molenaar, P.C., Vles, J.S., Bonifati, D.M., Verschuuren, J.J., van Doorn, P.A., Kuks, J.B., Wokke, J.H., Beeson, D. and De Baets, M. (2009) AChR Deficiency Due to Epsilon-Subunit Mutations: Two Common Mutations in the Netherlands. Journal of Neurology, 256, 1719-1723. http://dx.doi.org/10.1007/s00415-009-5190-7
|
[29]
|
Sieb, J.P., Kraner, S., Rauch, M. and Steinlein, O.K. (2000) Immature End-Plates and Utrophin Deficiency in Congenital Myasthenic Syndrome Caused by Epsilon-AChR Subunit Truncating Mutations. Human Genetics, 107, 160-164. http://dx.doi.org/10.1007/s004390000359
|
[30]
|
Payne, J.P., Hughes, R. and Al Azawi, S. (1980) Neuromuscular Blockade by Neostigmine in Anaesthetized Man. British Journal of Anaesthesia, 52, 69-76. http://dx.doi.org/10.1093/bja/52.1.69
|
[31]
|
Caldwell, J.E. (2009) Clinical Limitations of Acetylcholinesterase Antagonists. Journal of Critical Care, 24, 21-28. http://dx.doi.org/10.1016/j.jcrc.2008.08.003
|
[32]
|
Barber, H.E., Calvey, T.N. and Muir, K.T. (1979) The Relationship between the Pharmacokinetics, Cholinesterase Inhibition and Facilitation of Twitch Tension of the Quaternary Ammonium Anticholinesterase Drugs, Neostigmine, Pyridostigmine, Edrophonium and 3-Hydroxyphenyltrimethylammonium. British Journal of Pharmacology, 66, 525-530. http://dx.doi.org/10.1111/j.1476-5381.1979.tb13690.x
|
[33]
|
Stum, M., Girard, E., Bangratz, M., Bernard, V., Herbin, M., Vignaud, A., Ferry, A., Davoine, C.S., Echaniz-Laguna, A., René, F., Marcel, C., Molgó, J., Fontaine, B., Krejci, E. and Nicole, S. (2008) Evidence of a Dosage Effect and a Physiological Endplate Acetylcholinesterase Deficiency in the First Mouse Models Mimicking Schwartz-Jampel Syndrome Neuromyotonia. Human Molecular Genetics, 17, 3166-3179. http://dx.doi.org/10.1093/hmg/ddn213
|
[34]
|
Polansky, H. and Itzkovitz, E. (2013) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Pharmacology & Pharmacy, 4, 1-8. http://dx.doi.org/10.4236/pp.2013.46A001
|
[35]
|
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2004) Guidance for Industry. Botanical Drug Products. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation /Guidances/ucm070491.pdf http://dx.doi.org/10.1002/jmv.23411
|
[36]
|
Watt, T., Oberfoell, S., Balise, R., Lunn, M.R., Kar, A.K., Merrihew, L., Bhangoo, M.S. and Montoya, J.G. (2012) Response to Valganciclovir in Chronic Fatigue Syndrome Patients with Human Herpesvirus 6 and Epstein-Barr Virus IgG Antibody Titers. Journal of Medical Virology, 84, 1967-1974.
|
[37]
|
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2001) Guidance for Industry, E 10 Choice of Control Group and Related Issues in Clinical Trials. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129460.pdf
|
[38]
|
Breidert, M. and Hofbauer, K. (2009) Placebo: Misunderstandings and Prejudices. Deutsches Ärzteblatt International, 106, 751-755.
|
[39]
|
Willke, R.J., Burke, L.B. and Erickson, P. (2004) Measuring Treatment Impact: A Review of Patient-Reported Outcomes and Other Efficacy Endpoints in Approved Product Labels. Controlled Clinical Trials, 25, 535-552. http://dx.doi.org/10.1016/j.cct.2004.09.003
|
[40]
|
Harvey, P.D. and Keefe, R.S. (2001) Studies of Cognitive Change in Patients with Schizophrenia Following Novel Antipsychotic Treatment. The American Journal of Psychiatry, 158, 176-184. http://dx.doi.org/10.1176/appi.ajp.158.2.176
|
[41]
|
Schwartz, C.E., Bode, R. and Repucci, N. (2006) The Clinical Significance of Adaptation to Changing Health: A Meta-Analysis of Response Shift. Quality of Life Research, 15, 1533-1550. http://dx.doi.org/10.1007/s11136-006-0025-9
|
[42]
|
Chayavichitsilp, P., Buckwalter, J.V., Krakowski, A.C. and Friedlander, S.F. (2009) Herpes Simplex. Pediatrics in Review, 30, 119-129.
|
[43]
|
World Health Organization (WHO) (2010) Viral Cancers. http://www.who.int/vaccine_research/diseases/viral_cancers/en/index1.html
|
[44]
|
Staras, S.A., S Dollard, C., Radford, K.W., Flanders, W.D., Pass, R.F. and Cannon, M.J. (2006) Seroprevalence of Cytomegalovirus Infection in the United States, 1988-1994. Clinical Infectious Diseases, 43, 1143-1151. http://dx.doi.org/10.1086/508173
|
[45]
|
Grinde, B. (2013) Herpesviruses: Latency and Reactivation—Viral Strategies and Host Response. Journal of Oral Microbiology, 5, 22766. http://dx.doi.org/10.3402/jom.v5i0.22766
|